Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $28,000.

  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) rose 33.33% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $99,000, marking a year-over-year increase of 6.45%. This contributed to the annual value of $85,000 for FY2024, which is 43.71% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $28,000 for Q3 2025, which was down 3.45% from $29,000 recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Depreciation & Amortization (CF) peaked at $94,000 during Q3 2022, and registered a low of $20,000 during Q4 2024.
  • In the last 3 years, Corvus Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $28,000 in 2025 and averaged $28,636.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Depreciation & Amortization (CF) crashed by 70.21% in 2023, and later spiked by 38.10% in 2025.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Depreciation & Amortization (CF) stood at $94,000 in 2022, then tumbled by 70.21% to $28,000 in 2023, then dropped by 28.57% to $20,000 in 2024, then surged by 33.33% to $28,000 in 2025.
  • Its Depreciation & Amortization (CF) was $28,000 in Q3 2025, compared to $29,000 in Q2 2025 and $22,000 in Q1 2025.